Compare · NAMS vs NVO
NAMS vs NVO
Side-by-side comparison of NewAmsterdam Pharma Company N.V. (NAMS) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NAMS and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 50.6x NAMS ($3.62B).
- NVO has been more active in the news (8 items in the past 4 weeks vs 4 for NAMS).
- NVO has more recent analyst coverage (25 ratings vs 13 for NAMS).
- Company
- NewAmsterdam Pharma Company N.V.
- Novo Nordisk A/S
- Price
- $30.96-1.67%
- $41.01-4.51%
- Market cap
- $3.62B
- $183.15B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 4
- 8
- Recent ratings
- 13
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NAMS
- SEC Form S-8 filed by NewAmsterdam Pharma Company N.V.
- Amendment: SEC Form SCHEDULE 13G/A filed by NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Company N.V. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Chief Accounting Officer Kooij Louise Frederika exercised 65,000 units of Ordinary Shares at a strike of $10.07 and sold $2,319,850 worth of Ordinary Shares (65,000 units at $35.69) as part of a pre-agreed trading plan (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Company N.V. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by NewAmsterdam Pharma Company N.V.
- Amendment: SEC Form SCHEDULE 13G/A filed by NewAmsterdam Pharma Company N.V.
- SEC Form DEF 14A filed by NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Company N.V. filed SEC Form 8-K: Leadership Update
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care